Overview

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Completed
Trial end date:
2000-12-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed recurrent ovarian epithelial carcinoma,
fallopian tube cancer, or primary peritoneal cancer previously treated with at least one
cisplatin based chemotherapy regimen Prior repeat treatment with a taxane and/or platinum
agent allowed Prior repeat treatment with other chemotherapy agent allowed once Recurrent
disease defined as: At least one site of measurable disease by radiograph and/or a rise of
CA-125 over a minimum of 3 samples to a level of at least 50% of upper limit of normal

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life
expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3
Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 times upper limit of
normal (ULN) SGOT less than 2.0 times ULN Alkaline phosphatase less than 2.0 times ULN
Renal: Creatinine no greater than 1.5 mg/dL Other: Must be able to take oral medication

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No prior fluorouracil based chemotherapy Endocrine therapy: Not specified
Radiotherapy: Not specified Surgery: Not specified